References
- Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24–64.
- Tangye SG, Al-Herz W, Bousfiha A, et al. The ever-increasing array of novel inborn errors of immunity: an interim update by the IUIS Committee. J Clin Immunol. 2021;41(3):666–679.
- Burnet FM. The evolution of bodily defence. Med J Aust. 1963;2:817–821.
- Mortaz E, Tabarsi P, Mansouri D, et al. Cancers related to immunodeficiencies: update and perspectives. Front Immunol. 2016;7:365.
- Haas OA. Primary immunodeficiency and cancer predisposition revisited: embedding two closely related concepts into an integrative conceptual framework. Front Immunol. 2018;9:3136.
- Mayor PC, Eng KH, Singel KL, et al., Cancer in primary immunodeficiency diseases: cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol. 2018;141(3):1028–1035.
- Hauck F, Voss R, Urban C, et al. Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders. J Allergy Clin Immunol. 2018;141(1):59–68e54.
- Satge D, Tumor A. Profile in Primary Immune Deficiencies Challenges the Cancer Immune Surveillance Concept. Front Immunol. 2018;9:1149.
- Kiykim A, Eker N, Surekli O, et al. Malignancy and lymphoid proliferation in primary immune deficiencies; hard to define, hard to treat. Pediatr Blood Cancer. 2020;67(2):e28091.
- Riaz IB, Faridi W, Patnaik MM, et al. A systematic review on predisposition to Lymphoid (B and T cell) neoplasias in patients with primary immunodeficiencies and immune dysregulatory disorders (Inborn Errors of Immunity). Front Immunol. 2019;10:777.
- Ogulur I, Ertuzun T, Kocamis B, et al. Parents of ataxia-telangiectasia patients display a distinct cellular immune phenotype mimicking ATM-mutated patients. Pediatr Allergy Immunol. 2021;32(2):349–357.
- Vajdic CM, Mao L, Van Leeuwen MT, et al. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood. 2010;116(8):1228–1234.
- Bomken S, Van Der Werff Ten Bosch J, Attarbaschi A, et al. Current understanding and future research priorities in malignancy associated with inborn errors of immunity and DNA repair disorders: the perspective of an Interdisciplinary Working Group. Front Immunol. 2018;9:2912.
- Cohen JM, Sebire NJ, Harvey J, et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation. Blood. 2007;110(6):2209–2214.
- Cekic S, Metin A, Aytekin C, et al. The evaluation of malignancies in Turkish primary immunodeficiency patients; a multicenter study. Pediatr Allergy Immunol. 2020;31(5):528–536.
- Mellemkjaer L, Hammarstrom L, Andersen V, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol. 2002;130(3):495–500.
- Tanyildiz HG, Dincaslan H, Yavuz G, et al., Lymphoma secondary to congenital and acquired immunodeficiency syndromes at a Turkish Pediatric Oncology Center. J Clin Immunol. 2016;36(7):667–676.
- Kiykim A, Ogulur I, Dursun E, et al. Abatacept as a long-term targeted therapy for LRBA deficiency. J Allergy Clin Immunol Pract. 2019;7(8):2790–2800 e2715.
- Kolukisa B, Baris S. Primary immune regulatory disorders and targeted therapies. Turk J Haematol. 2021;38(1):1–14.
- Magg T, Schober T, Walz C, et al. Epstein-Barr Virus(+) smooth muscle tumors as manifestation of primary immunodeficiency disorders. Front Immunol. 2018;9:368.